… Nilotinib and dasatinib showed a tendency towards a higher risk of DDI compared with
imatinib. There were no significant differences in AE frequency or in treatment response between …

… of a single TKI-associated interaction (imatinib-simvastatin, 14.5% of imatinib patients). The
… agents included in this analysis (dasatinib, erlotinib, nilotinib) contain information on drug …

… Nilotinib Patients P-gp inhibition Imatinib increase intracellular concentration of nilotinib …
tea on BCRP has been demonstrated in vitro with dasatinib as a dual substrate of P-gp and …

… Besides imatinib, dasatinib and nilotinib have expanded therapeutic options for pediatric
CML treatment. Ongoing investigations into bosutinib and ponatinib show promise as potential …

… Imatinib was the first BCR-ABL tyrosine kinase inhibitor (TKI) … of ABL TKIs, including
nilotinib, dasatinib, ponatinib, and … properties of nilotinib, drug-drug and food-drug interactions, …

… One lesson derived from the dasatinib clinical experience is … Nilotinib and dasatinib have
worked their way up to … trials of nilotinib versus imatinib (5) and of dasatinib versus imatinib (6) …

… case of imatinib, dasatinib and sunitinib (9). The activity of CYP3A4 is regulated by various
factors, including drug interactions, … with a different TKI such as nilotinib or dasatinib (16). The …

… Methods: We checked DDIs of 100 drugs with six BCR-ABL TKIs—dasatinib, imatinib,
nilotinib, ponatinib, bosutinib, and asciminib—in two subscription-based databases (UpToDate …

… of aniline-containing drugs and has been reported for … second generations (dasatinib,
erlotinib, gefitinib, imatinib, and … proposed for imatinib,50 a TKI structurally close to nilotinib. The …

… To overcome the drug resistance phenomenon induced by Imatibib (IM), in … of tyrosine
kinase inhibitors as Nilotinib (NIL); a such potent inhibitor of the BCR/ABL kinase and Dasatinib (…